6.
Saeed S, Thomas T, Dinh D, Moodie E, Cox J, Cooper C
. Frequent Disengagement and Subsequent Mortality Among People With HIV and Hepatitis C in Canada: A Prospective Cohort Study. Open Forum Infect Dis. 2024; 11(5):ofae239.
PMC: 11127478.
DOI: 10.1093/ofid/ofae239.
View
7.
Mendlowitz A, Bremner K, Krahn M, Walker J, Wong W, Sander B
. Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study. CMAJ. 2023; 195(14):E499-E512.
PMC: 10089629.
DOI: 10.1503/cmaj.220717.
View
8.
Saeed S, Strumpf E, Moodie E, Wong L, Cox J, Walmsley S
. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019; 71(2):363-371.
PMC: 7353326.
DOI: 10.1093/cid/ciz833.
View
9.
Pearce M, Jongbloed K, Demerais L, Macdonald H, Christian W, Sharma R
. "Another thing to live for": Supporting HCV treatment and cure among Indigenous people impacted by substance use in Canadian cities. Int J Drug Policy. 2019; 74:52-61.
DOI: 10.1016/j.drugpo.2019.08.003.
View
10.
Krajden M, Cook D, Janjua N
. Contextualizing Canada's hepatitis C virus epidemic. Can Liver J. 2022; 1(4):218-230.
PMC: 9202764.
DOI: 10.3138/canlivj.2018-0011.
View
11.
Williams K, Dunn K, Lee S
. The Canadian hepatitis C treatment landscape: Time to turn chaos into order. Can Liver J. 2023; 6(2):187-189.
PMC: 10370726.
DOI: 10.3138/canlivj-2023-0008.
View
12.
Dale C, Smith E, Biondi M
. Nurse practitioners as primary care site champions for the screening and treatment of hepatitis C virus. J Am Assoc Nurse Pract. 2022; 34(4):688-695.
DOI: 10.1097/JXX.0000000000000689.
View
13.
Northrop J
. A dirty little secret: stigma, shame and hepatitis C in the health setting. Med Humanit. 2017; 43(4):218-224.
DOI: 10.1136/medhum-2016-011099.
View
14.
Goldenberg S, Montaner J, Braschel M, Socias E, Guillemi S, Shannon K
. Dual sexual and drug-related predictors of hepatitis C incidence among sex workers in a Canadian setting: gaps and opportunities for scale-up of hepatitis C virus prevention, treatment, and care. Int J Infect Dis. 2016; 55:31-37.
PMC: 5369649.
DOI: 10.1016/j.ijid.2016.12.019.
View
15.
Yazdani K, Dolguikh K, Zhang W, Shayegi-Nik S, Ly J, Cooper S
. Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy. PLoS One. 2022; 17(3):e0265811.
PMC: 8942206.
DOI: 10.1371/journal.pone.0265811.
View
16.
Bouzanis K, Joshi S, Lokker C, Pavalagantharajah S, Qiu Y, Sidhu H
. Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review. BMJ Open. 2021; 11(9):e047511.
PMC: 8461723.
DOI: 10.1136/bmjopen-2020-047511.
View
17.
Pearce M, Jongbloed K, Richardson C, Henderson E, Pooyak S, Oviedo-Joekes E
. The Cedar Project: resilience in the face of HIV vulnerability within a cohort study involving young Indigenous people who use drugs in three Canadian cities. BMC Public Health. 2015; 15:1095.
PMC: 4625636.
DOI: 10.1186/s12889-015-2417-7.
View
18.
Dunn K, Williams K, Egan C, Potestio M, Lee S
. ECHO+: Improving access to hepatitis C care within Indigenous communities in Alberta, Canada. Can Liver J. 2022; 5(2):113-123.
PMC: 9236587.
DOI: 10.3138/canlivj-2021-0027.
View
19.
Tarasuk J, Sullivan M, Bush D, Hui C, Morris M, Starlight T
. Findings among Indigenous participants of the Tracks survey of people who inject drugs in Canada, Phase 4, 2017-2019. Can Commun Dis Rep. 2021; 47(1):37-46.
PMC: 7919774.
DOI: 10.14745/ccdr.v47i01a07.
View
20.
Popovic N, Williams A, Perinet S, Campeau L, Yang Q, Zhang F
. National Hepatitis C estimates: Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019. Can Commun Dis Rep. 2024; 48(11-12):540-549.
PMC: 10786238.
DOI: 10.14745/ccdr.v48i1112a07.
View